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Abstract Activation of the signal transducer and activator of
transcription 3 (STAT3) in response to interleukin-6 (IL-6) type
cytokines involves both phosphorylation of Tyr705, which
enables dimerization, nuclear translocation and DNA binding,
as well as ser727 phosphorylation. Here, we describe that the 65
C-terminal amino acids of STAT3 can function as an
independent transcription activation domain (TAD), particularly
when a negative charge is introduced at position 727 by mutation
of the serine residue into aspartate. The strong transcriptional
activity of the C-terminal STAT3 Ser727Asp TAD is coupled to
a constitutive association with the co-activator p300. In HepG2
cells, p300 associates with STAT3 upon IL-6 stimulation, and
overexpression of p300 enhances the transcriptional activity of
STAT3K, but not of STAT3L or STAT3 Ser727Ala. We
conclude that Ser727 phosphorylation in the C-terminal region
of STAT3 is required for transactivation by association with
p300. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The signal transducer and activator of transcription (STAT)
family of transcription factors is activated in response to a
variety of extracellular ligands [1,2]. Currently, seven mamma-
lian STATs have been identi¢ed which all become phosphor-
ylated on a tyrosine residue in response to cell-surface recep-
tor activation allowing STAT dimerization, nuclear
translocation and transcription activation [1,2]. All STATs
have crucial physiological roles during embryogenesis, devel-
opment, hematopoiesis and immune responses, while each
STAT serves a highly speci¢c function [3,4]. Isoforms of at
least STAT1 and STAT3 exist, designated as STAT1L and
STAT3L, respectively, which both lack a C-terminal region
due to di¡erential splicing [5^7]. STAT1L and STAT3L have
strongly reduced transcriptional activities as compared to wild
type STAT1K and STAT3K, indicating the C-terminal region
serves as an important transactivation domain (TAD) [5,6].
Indeed, phosphorylation of a speci¢c serine residue located in
the TAD, Ser727 in both STAT1 and STAT3, is required to
achieve maximal transcriptional activity [8,9].
Most transcription factors function in multi-protein enhan-
ceosomes to initiate gene transcription. Interactions of STATs
have been described with hormone receptors, mini-chromo-
some maintenance proteins, members of the AP-1 family
and members of the interferon (IFN) regulatory factor family
[10^15]. Also, interactions between some STATs and CREB
binding protein (CBP)/p300 have been described [16^18]. The
p300 and CBP transcriptional co-activators are important reg-
ulators of many cellular processes. They contain histone ace-
tyltransferase (HAT) domains, are involved in chromatin re-
modeling [19], and interact with a wide range of DNA binding
transcription factors, including p53, E2F, AP-1, nuclear re-
ceptors, MyoD, and the p65 subunit of nuclear factor UB
[20,21]. Speci¢cally, p300/CBP has been reported to interact
with STAT1, where both the N-terminal as well as the C-
terminal region of STAT1 appear to be involved in its asso-
ciation with p300/CBP [18]. Also, p300/CBP interactions with
STAT5 have been described [22].
However, it is unclear to what extend such interactions are
of importance for optimal STAT3 transactivation. The experi-
ments presented here were designed to study the role of
Ser727 phosphorylation in relation to association with other
proteins. We report that the 65 C-terminal amino acids of
STAT3 can serve as an independent TAD. p300/CBP associ-
ates with STAT3 in response to interleukin-6 (IL-6) stimula-
tion, whereas it is constitutively associated with the C-termi-
nal region of the STAT3 Ser727Asp mutant. Furthermore, we
demonstrate that overexpression of p300/CBP enhances
STAT3K, but not STAT3L or STAT3 Ser727Ala, transcrip-
tional activities.
2. Materials and methods
2.1. Cell culture and antibodies
HepG2 and COS7 cells were grown in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% heat-inactivated fetal calf serum (In-
tegro B.V., Zaandam, The Netherlands). Cells were stimulated with 25
ng/ml human recombinant IL-6 [23]. Antibodies against STAT3 (C-
20) and p300 (C-20) (Santa Cruz) were used in dilutions of 1:4000.
The antibodies against the DNA binding domain of GAL4 were ob-
tained from Upstate Technology and were used in a dilution of
1:1000.
2.2. Reporters, expression vectors and plasmid constructions
The pIRE-ti-LUC reporter was made by inserting a synthetic oli-
gonucleotide (5P-ctagcaggTTTCCGGGAAAgcacagcttaggTTTCCGG-
GAAAgcac-3P) containing two copies of the IL-6 response element
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(IRE) of the ICAM-1 promoter in the NheI site of the pGL3ti min-
imal promoter luciferase construct as described previously [24]. The
UAS-GAL4-luciferase reporter contains ¢ve copies of the GAL4
binding site in front of the luciferase gene. Furthermore, the following
eukaryotic expression vectors were used: pSG5-STAT3K, encoding
human STAT3K (generous gift from Dr. P. Co¡er, Department of
Pulmonary Diseases, AZU, Utrecht, The Netherlands); pSG5-
STAT3L encoding human STAT3L (generous gift from Dr. R. de
Groot, Department of Pulmonary Diseases, AZU, Utrecht, The Neth-
erlands) [5]; and pSG5-STAT3 Ser727Ala, encoding the Ser727Ala
mutant of STAT3 [25]. The mutant pSG5-STAT3 Ser727Asp was
cloned by site-directed mutagenesis and the sequence was con¢rmed
by sequencing. The expression vector pCMV-p300 was obtained from
Dr. D.M. Livingston. pGAD424-STAT3K (502^771), pGAD424-
STAT3K (599^771), pGAD424-STAT3K (705^771), pGAD424-
STAT3 Ser727Asp (502^771), pGAD424-STAT3 Ser727Asp (599^
771), and pGAD424-STAT3 Ser727Asp (705^771) were constructed
by PCR using pSG5-STAT3K or pSG5-STAT3 Ser727Asp as tem-
plates and the following primers: (502) 5P-GAGAATTCGAC-
CAAGTGGCCGAGG-3P, (599) 5P-GAGAATTCAGCACTAAGC-
CCCCAG-3P, (705) 5P-GAGAATTCCTGAAGACCAAGTTTATC-
TGTGTG-3P, all containing an EcoRI site in the £anking sequence,
and (reverse) 5P-GCGAGCTCTCACATGGGGGAGGTAG-3P which
contains an SacI site in the £anking sequence. PCR products were cut
with EcoRI and SacI and the fragments were cloned into the EcoRI
and SacI sites of pGAD424.
2.3. Transient transfection assays
HepG2 cells were seeded at 3U105 cells per well in 6-well plates
(Costar), and 24 h later cells were transfected with 10 Wg plasmid
DNA using the calcium phosphate co-precipitation method [26].
Transfection mixtures consisted of a mixture of 2.5 Wg reporter, 2.5
Wg pDM2-LacZ as a control to determine transfection e⁄ciency, and
2.5 Wg expression plasmids unless stated otherwise in Section 3. When
necessary, pUC18 was added to the transfection mixture to obtain a
total of 10 Wg of DNA. Cells were incubated with precipitate for 24 h,
washed with phosphate-bu¡ered saline (PBS), and stimulated for an
additional 24 h. Cells were collected in 200 Wl reporter lysis bu¡er
(Promega) and subjected to the assays for luciferase and L-galactosi-
dase as previously described [25]. Experiments were performed in
triplicate and representative examples of at least three independent
experiments are shown. Standard deviations were calculated using
Sigmaplot (Jandel Corp.).
2.4. Western blotting and immunoprecipitations
A total of 1U107 cells were lysed on ice in lysis bu¡er (100 mM
NaCl pH 7.4, 2 mM EGTA, 1 mM dithiothreitol, 1 mM Na2VO3
(ortho), 1% Triton X-100, 10% glycerol, 10 Wg/ml leupeptin, and 0.4
mM PMSF). Protein concentrations were determined (Bio-Rad).
Whole-cell extracts were boiled for 5 min in the presence of Laemmli
sample bu¡er prior to separation on 12.5% sodium dodecyl sulfate
(SDS)^polyacrylamide gels. The proteins were transferred to a nitro-
cellulose ¢lter (Millipore) in Tris-glycine bu¡er at 100 V for 1.5 h
using an electroblotter (Pharmacia). Membranes were blocked with
PBS bu¡er containing 5% non-fat milk prior to incubation with anti-
bodies. Binding of each antibody was detected by chemiluminescence
using ECL according to the manufacturer’s recommendations (Amer-
sham Corp.). For immunoprecipitations, whole-cell lysates were incu-
bated with 1 Wg of antibodies, precipitated with Protein-A Sepharose
beads (Pharmacia), and washed three times with lysis bu¡er. The
precipitates were boiled for 5 min in Laemmli sample bu¡er and
subjected to 12.5% SDS^polyacrylamide gel electrophoresis.
3. Results
3.1. The role of the C-terminus in STAT3 transactivation
In order to study the functional role of the C-terminus in
STAT3 transactivation, STAT3K, STAT3L and the point mu-
tants STAT3 Ser727Ala and STAT3 Ser727Asp were transi-
ently overexpressed in COS7 cells which express low levels of
endogenous STAT3. As depicted in Fig. 1A, overexpression of
STAT3K resulted in an approximately 4-fold induction of
reporter activation in response to IL-6, while overexpression
of STAT3L did not signi¢cantly induce reporter activation.
Overexpression of STAT3 Ser727Ala resulted in a 1.5-fold
induction of reporter activation in response to IL-6, while
STAT3 Ser727Asp enhanced reporter activation to higher lev-
els than wild type. These data con¢rm that the C-terminal
region is important for maximal STAT3 transcriptional activ-
ity and suggest that phosphorylation of the serine residue 727
serves to provide a negative charge on the molecule.
Recently, we have demonstrated that IL-6 induced STAT3
Ser727 phosphorylation and that transactivation requires ac-
tivation of the GTPase Rac-1 [25]. To test whether the STAT3
Ser727Asp mutant has become independent of IL-6-induced
Rac-1 activity, STAT3K or STAT3 Ser727Asp were transi-
ently overexpressed in HepG2 cells together with dominant
negative RacN17. As depicted in Fig. 1B, overexpression of
dominant negative RacN17 severely impaired IL-6-induced
activation of STAT3K, whereas STAT3 Ser727Asp transacti-
vation remained una¡ected. These data indicate that IL-6-in-
Fig. 1. The C-terminal region of STAT3 is required to achieve max-
imal transactivation. A: COS7 cells were transiently transfected with
the IRE-LUC reporter, together with expression vectors for
STAT3K, STAT3L, STAT3 Ser727Ala or STAT3 Ser727Asp as indi-
cated. Cells were stimulated with 25 ng/ml IL-6 for 24 h prior to
harvest and luciferase and LacZ assays. Experiments were per-
formed in triplicate and a representative example of three independ-
ent experiment is shown. B: HepG2 cells were transiently trans-
fected with the IRE-LUC reporter together with expression vectors
for STAT3K, STAT3 Ser727Asp and dominant negative RacN17 as
indicated. Cells were stimulated with 25 ng/ml IL-6 for 24 h prior
to harvest and luciferase and LacZ assays.
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duced activation of the STAT3 Ser727Asp mutant is inde-
pendent of activation of the Rac-1 signal transduction cas-
cade.
3.2. De¢ning the minimal STAT3 transactivation domain
In order to identify the minimal STAT3 transactivation
domain, a series of GAL4-STAT3 chimeras were constructed
in which C-terminal fragments of either STAT3K or STAT3
Ser727Asp were fused to the DNA binding domain of GAL4
(Fig. 2A). Transcriptional activities of chimeras were tested on
the UAS-luciferase reporter by transient transfection in
HepG2 cells. Overexpression of GAL4-STAT3K (705) en-
hanced reporter activation 4-fold over basal levels, compara-
ble to the transcriptional activities of GAL4-STAT3K (599)
(Fig. 2B). In contrast, GAL4-STAT3K (502) did not drive
reporter activation. Surprisingly, in each case IL-6 did not
further enhance transcription activation, which may suggest
that STAT3 dimerization is a prerequisite for Ser727 phos-
phorylation. GAL4-STAT3 (705) Ser727Asp strongly en-
hanced reporter activation approximately 200-fold over basal
levels, while GAL4-STAT3 (599) Ser727Asp induced a 16-fold
induction of reporter activation. GAL4-STAT3 (502) Ser727-
Asp did not induce activation of the reporter. Again, IL-6 did
not further enhance transcriptional activities of the GAL4-
STAT3 Ser727Asp chimeras. All proteins were expressed to
comparable levels (Fig. 2C). These data indicate that the C-
terminal 65 amino acids of STAT3 can serve as a minimal
TAD, particularly if a negative charge is introduced at posi-
tion 727.
3.3. The minimal TAD of STAT3 Ser727Asp is constitutively
associated with p300
Next, it was investigated whether p300 was associated with
the GAL4-STAT3 chimeras thus driving the transcriptional
activities. GAL4-STAT3 (705) Ser727Asp, GAL4-STAT3
(599) Ser727Asp and GAL4 were overexpressed in HepG2
cells, and cells were either stimulated with IL-6 for 15 min
or left unstimulated. The GAL4-STAT3 chimeras were immu-
noprecipitated from total cell extracts by using anti-GAL4
antibodies and immunoprecipitates were blotted against
p300. Comparable amounts of GAL4 or GAL4-STAT3 chi-
meras were immunoprecipitated, while p300 co-immunopreci-
pitated with GAL4-STAT3 (705) Ser727Asp, and to a lesser
degree with GAL4-STAT3 (599) Ser727Asp (Fig. 3, lanes 1^
4). IL-6 stimulation did not in£uence the amount of co-im-
munoprecipitated p300. p300 did not co-immunoprecipitate
with GAL4 and no a-speci¢c binding of p300 to the beads
was observed (Fig. 3, lanes 5^7). Also, no signi¢cant p300
association was observed with GAL4-STAT3K (705) or
GAL4-STAT3K (599) (data not shown). These data correlate
Fig. 2. De¢ning the minimal STAT3 transactivation domain. A: Schematic view of the GAL4-STAT3 chimeras used in this study: C-terminal
fragments of STAT3K or STAT3 Ser727Asp (regions 502^770, 599^770 and 705^770) were fused to the DNA binding domain of GAL4. B:
HepG2 cells were transiently transfected with the UAS-LUC reporter together with expression vectors for the GAL4-STAT3 chimeras as indi-
cated. Cells were stimulated with 25 ng/ml IL-6 for 24 h prior to harvest and luciferase and LacZ assays. C: GAL4-STAT3 chimeras were
overexpressed in HepG2 cells and total cell lysates were Western blotted using antibodies against the DNA binding region of GAL4.
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well with the levels of transcriptional activity of the GAL4-
STAT3 chimeras.
3.4. p300 associates with STAT3 upon IL-6 stimulation
To determine whether p300 also associates with STAT3 in
vivo, HepG2 cells were stimulated with IL-6 or left unstimu-
lated and nuclear extracts were prepared. Endogenous p300
was immunoprecipitated, and immunoprecipitates were blot-
ted against STAT3. As depicted in Fig. 4, STAT3 translocated
to the nucleus upon IL-6 stimulation (lower panel), and asso-
ciated with p300 (upper panel). No a-speci¢c association of
STAT3 with the beads was observed (data not shown). These
data indicate that STAT3 associates with p300 in vivo in the
nucleus upon IL-6 stimulation.
3.5. The e¡ects of p300 overexpression on
STAT3 transcriptional activity
Since p300 associated with STAT3 in vivo, the functionality
of this interaction was studied on a STAT3 responsive IRE-
luciferase reporter in COS7 cells. Increasing amounts of p300
were overexpressed which strongly enhanced STAT3K trans-
activation at low concentrations, but inhibited STAT3K trans-
activation at high concentrations (Fig. 5A). Similar patterns
of reporter activation were observed in the presence of over-
expressed STAT3 Ser727Asp (Fig. 5B). In contrast, in the
presence of overexpressed STAT3L or STAT3 Ser727Ala,
IL-6 did not signi¢cantly enhance reporter activation, and
overexpression of p300 did not alter STAT3 transcriptional
activities (Fig. 5C,D). These data indicate that p300 speci¢-
cally a¡ects transcriptional activities via interaction with the
Ser727 residue in the C-terminal region of STAT3.
4. Discussion
STAT1, STAT3 and STAT4 all share a conserved stretch of
amino acids in their C-terminal region (LPMSP) in which
both the leucine as well as the serine residues are important
Fig. 3. The minimal TAD of STAT3 Ser727Asp is constitutively associated with p300. GAL4, GAL4-STAT3 (705) Ser727Asp and GAL4-
STAT3 (599) Ser727Asp were overexpressed in HepG2 cells, cells were either stimulated with 25 ng/ml IL-6 for 15 min or left unstimulated
and lysates were prepared as described in Section 2. Immunoprecipitations were performed using anti-GAL4 antibodies and precipitates were
blotted against p300 and GAL4. Also, the endogenous levels of p300 are shown in each sample as a loading control. As a negative control, ly-
sates were incubated with beads alone in the absence of anti-GAL4 antibody.
Fig. 4. p300 associates with STAT3 in vivo upon IL-6 stimulation.
HepG2 cells were stimulated with 25 ng/ml IL-6 for 15 min or left
unstimulated, nuclear extracts were prepared as described in Section
2 and p300 was immunoprecipitated using anti-p300 antibody. Im-
munoprecipitates were blotted against STAT3 and p300. As a load-
ing control, total levels of STAT3 expression are shown.
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to achieve maximal transactivational activity [2,8,27]. Upon
cytokine or growth factor stimulation, the serine residue be-
comes phosphorylated, and it has been well documented that
this phosphorylation event is critical in order to initiate high
levels of gene transcription in various cellular settings [28,29].
Isoforms of STAT1 and STAT3 exist, designated as STAT1L
and STAT3L, which lack a C-terminal region that contains
the LPMSP motif due to splicing events, and these isoforms
display reduced transcriptional activities [5,6]. These studies
suggested that the C-terminal regions of STAT1 and STAT3
serve as a transcription activation domain (TAD). However,
the mechanisms underlying these observations are not well
de¢ned.
Here, we con¢rm that Ser727 phosphorylation of the C-
terminal region of STAT3 is required to achieve maximal
transcriptional activity in response to IL-6 stimulation. In
the presence of overexpressed STAT3L or STAT3 Ser727Ala,
IL-6 only induced low reporter activation as compared to
STAT3K as determined with IRE-luciferase reporter assays
in COS7 cells. When the STAT3 Ser727Asp mutant was over-
expressed, IL-6 stimulation was still required to induce
STAT3 Tyr705 phosphorylation and dimerization, while the
IL-6-induced transactivation was not signi¢cantly di¡erent
from wild type. This indicates that a negative charge at posi-
tion 727 does not signi¢cantly a¡ect IL-6-induced Tyr705
phosphorylation or nuclear import. gp130-mediated STAT3
activation involves STAT3 Tyr705 phosphorylation via JAK
tyrosine kinases, while the IL-6-induced STAT3 Ser727 phos-
phorylation involves activation of a signal transduction cas-
cade that is comprised of the gp130-associated guanine nucle-
otide exchange factor Vav, the small GTPase Rac-1 and the
kinases MEKK-1 and SEK-1/MKK-4 [25]. Here, we demon-
strate that IL-6-induced activation of the STAT3 Ser727Asp
mutant is independent of the Rac-1-mediated signal transduc-
tion cascade, indicating that the role of this signal transduc-
tion pathway is to provide STAT3 with a negative charge at
position 727.
The 65 C-terminal amino acids of STAT3 can serve as an
independent TAD, since fusion of this domain to the DNA
binding region of GAL4 strongly enhanced reporter activa-
tion, particularly when a negative charge was introduced at
position 727. The strong transcriptional activity of GAL4-
STAT3 (705) Ser727Asp is coupled to a strong and constitu-
tive association with the co-activator p300, suggesting that
p300 might serve as a bridging factor between STAT3 and
the basal transcription machinery. These data also indicate
that dimerization of STAT3 is not required for its association
with p300. p300 associated to a lesser extend with GAL4-
STAT3 (599) Ser727Asp, while no p300 association was de-
tected with the TAD domain regions of STAT3K which cor-
related well with their transcriptional activities, respectively.
Surprisingly, the longest C-terminal region of STAT3 (502^
770) did not induce reporter activation nor associated with
p300, even when Ser727 was mutated into aspartate. Possibly,
steric e¡ects account for these observations or alternatively, it
is conceivable that the linker region of STAT3 contains motifs
that negatively regulate STAT3 transactivation. Further ex-
periments are required to resolve these issues. Furthermore,
it is intriguing that the transcriptional activity of the C-termi-
nal TAD of STAT3K is not further enhanced upon IL-6 stim-
ulation. These data suggest that a STAT3 monomer is not
phosphorylated on Ser727, but that IL-6-induced Ser727
phosphorylation requires a STAT3 dimer. Similar mecha-
nisms have been described for the transcription factor AP-1,
Fig. 5. The e¡ects of p300 overexpression of STAT3 transactivation. COS7 cells were transiently transfected with the IRE-LUC reporter, to-
gether with expression vectors for STAT3K (A), STAT3 Ser727Asp (B), STAT3L (C) or STAT3 Ser727Ala (D) as indicated. Increasing
amounts of p300 were overexpressed as indicated in each experiment. Cells were stimulated with 25 ng/ml IL-6 for 24 h prior to harvest and
luciferase and LacZ assays.
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which is comprised of homo- or heterodimers of c-Fos, c-Jun
or other Jun family members, for which dimerization is a
prerequisite for serine phosphorylation by JNK-1 [30].
Whether similar mechanisms also apply for STAT3 activation
requires further experiments, but comparable observations
published by Zhang et al. have demonstrated that the trans-
activation of GAL4-STAT1 monomers is not further en-
hanced upon IFN-Q stimulation [14].
In vivo, p300 associates with STAT3 upon IL-6 stimulation,
suggesting that both nuclear translocation and serine phos-
phorylation are required to enable STAT3^p300 complex for-
mation. Since overexpression of p300 enhances both STAT3K
as well as STAT3 Ser727Asp transcriptional activities, we
conclude that the Ser727 phosphorylation in the C-terminus
is required for the p300 driven transcriptional activity of
STAT3. This is also further supported by the ¢nding that
the transactivation of STAT3L or STAT3 Ser727Ala is not
enhanced by p300 overexpression. Similar mechanisms have
been described for c-Jun and p53, where phosphorylation of
serine residues is a prerequisite for association with p300 and
high transcriptional activities [31,32]. Unexpectedly, high con-
centrations of p300 reduced STAT3 transactivation. Possibly,
squelching e¡ects account for these observations.
An important issue concerns the mechanism by which p300
enhances STAT3 transactivation. Since p300 contains a HAT
domain which is required for the cooperative transcriptional
activity with c-Jun and p53 [31,32], it is conceivable that HAT
activity is also required for its cooperativity with STAT3.
However, we can exclude the possibility that p300 directly
acetylates STAT3, since no acetylation of STAT3 was ob-
served in response to IL-6 using a pan-Acetyl antibody in
Western blotting experiments (J.J. Schuringa et al., unpub-
lished observations). Alternatively, it is plausible that p300
enhances STAT3 transactivation by functioning as a bridging
factor coupling DNA-bound, Ser727 phosphorylated STAT3
to the basic transcription machinery via association of p300
with TBP (TATA binding protein) [33^35]. Taken together,
our data provide a mechanism via which the C-terminal TAD
of STAT3 enables high levels of gene transcription by associ-
ation with p300.
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